3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
13
Gastrointestinal
7
Breast
3
Thoracic
2
Sarcoma
1
Plasma cell
1
Myeloid
1
Head & Neck
1
Genitourinary
1
CNS
1
Conditions
Nasopharyngeal Carcinoma
71
Nasopharyngeal Neoplasms
25
Head and Neck Neoplasms
25
Squamous Cell Carcinoma of Head and Neck
18
Neoplasm Metastasis
14
Carcinoma, Non-Small-Cell Lung
11
Recurrence
9
Salivary Gland Neoplasms
7
Ovarian Neoplasms
7
Stomach Neoplasms
6
Pancreatic Neoplasms
6
Small Cell Lung Carcinoma
5
Prostatic Neoplasms
5
Neoplasms
5
Melanoma
5
Colorectal Neoplasms
5
Breast Neoplasms
5
Triple Negative Breast Neoplasms
4
Sarcoma
4
Lung Neoplasms
4
Esophageal Neoplasms
4
Urinary Bladder Neoplasms
3
Thyroid Neoplasms
3
Laryngeal Diseases
3
Epstein-Barr Virus Infections
3
Colonic Neoplasms
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Osteosarcoma
2
Oropharyngeal Neoplasms
2
Mouth Neoplasms
2
Interventions
pembrolizumab
19
Paclitaxel
6
Trastuzumab
5
Nivolumab
5
palbociclib
4
Carboplatin
4
Biopsy
4
lenvatinib
3
Taxes
3
Specimen Handling
3
Magnetic Resonance Spectroscopy
3
Ipilimumab
3
Immunoglobulin G
3
Fulvestrant
3
Cyclophosphamide
3
Cetuximab
3
trastuzumab deruxtecan
2
tisotumab vedotin
2
spartalizumab
2
sargramostim
2
gedatolisib
2
fludarabine
2
epacadostat
2
capivasertib
2
X-Rays
2
Sunitinib
2
Docetaxel
2
Disulfides
2
Cisplatin
2
Bevacizumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Endometrial Neoplasms
×
Gemcitabine
×
Head & Neck
×
Clear all
NCT05007106
2025-08-14
KEYVIBE-005
Merck Sharp & Dohme LLC
Phase 2
Completed
613 enrolled